	US 12,460,185 B2
	Optimized cannabinoid synthase polypeptides
Andrew Horwitz, Oakland, CA (US); Jeff Wong, Berkeley, CA (US); Darren Platt, San Francisco, CA (US); and Jeff Ubersax, San Francisco, CA (US)
Assigned to Demetrix, Inc., Berkeley, CA (US)
Filed by Demetrix, Inc., Berkeley, CA (US)
Filed on Nov. 19, 2021, as Appl. No. 17/531,123.
Application 17/531,123 is a continuation of application No. PCT/US2020/033555, filed on May 19, 2020.
Claims priority of provisional application 62/906,551, filed on Sep. 26, 2019.
Claims priority of provisional application 62/906,017, filed on Sep. 25, 2019.
Claims priority of provisional application 62/851,560, filed on May 22, 2019.
Prior Publication US 2022/0228130 A1, Jul. 21, 2022
Int. Cl. C12N 15/52 (2006.01); C12N 9/02 (2006.01); C12N 15/81 (2006.01); C12P 7/22 (2006.01); C12P 17/06 (2006.01)

CPC C12N 9/0004 (2013.01) [C12N 15/81 (2013.01); C12P 7/22 (2013.01); C12P 17/06 (2013.01); C12Y 121/03008 (2015.07)]

27 Claims

1. An engineered variant of a cannabidiolic acid synthase (CBDAS) polypeptide comprising an amino acid sequence of SEQ ID NO:3 with one or more amino acid substitutions, wherein said one or more amino acid substitutions occurs at an amino acid selected from the group consisting of C12, F17, F18, S20, R31, N33, P43, L49, K50, L51, Q55, N56, N57, L59, M61, S62, V63, S66, L71, S75, 197, L98, S100, V103, T109, Q124, V125, 1129, L132, S137, V149, W161, K165, E167, S170, L171, A172, Y175, C180, A181, H208, A235, A250, M256, K260, L268, H309, T310, F316, L326, G378, K389, E406, M412, L415, S428, L439, 1445, N466, Y499, N527, P538, R541, H542, R543, and H544, and

wherein the amino acid sequence has at least 85% sequence identity to SEQ ID NO:3.